Amolyt Pharma

📍 Ecully, France🗓 Founded 2015👥 49 employees💰 Last funded Jan 2023
Biotechnology Research🌐 amolytpharma.com
Website LinkedIn
Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.
3
Total investors
0
Early stage
0
Mid stage
3
Late stage
2015
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
United States
1
Cyprus
1
Canada
1
Investor activity2021–2023 · investors recorded per year
2021220231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Amolyt Pharma?
Amolyt Pharma has 3 investors on record on gritt.io and 3 late-stage investors.
When did Amolyt Pharma last raise funding?
The most recent investment in Amolyt Pharma recorded on gritt.io was in January 2023.
When was Amolyt Pharma founded?
Amolyt Pharma was founded in 2015.
What industry is Amolyt Pharma in?
Amolyt Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Amolyt Pharma based?
Amolyt Pharma is headquartered in Ecully, France.